Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva flags supply constraints to ADHD drug Adderall as demand rises (NYSE: TEVA) | Seeking Alpha
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Teva's Working With Evercore to Review Debt Options - Bloomberg
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Justice Dept reportedly may file charges in its generic-drug probe by year-end
With New Teva Deal, Combined NY Settlements With Opioid Makers Top $2 Billion | New York Law Journal
Teva Pharmaceutical: Value at Last - WSJ
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Teva Agrees to Settle Opioid Lawsuits for as Much as $4.25 Billion - WSJ
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva: Now What? | Barron's
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva Stares Into Abyss as It Slashes Forecast, Dividends - Bloomberg
HSBC downgrades Teva on uncertainty surrounding DOJ's reported generic drug investigation
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
US states sue Teva for price-fixing in 'multi-billion dollar fraud' | The Times of Israel
CVS, Teva, Allergan and Endo reach $878 million deal with Florida over the opioid crisis - STAT
Teva looks to sell generics in China through joint venture with Guangzhou Pharma: Bloomberg | Fierce Pharma
Teva Considering Cutting up to 10,000 Jobs: Bloomberg
